WallStreetZenWallStreetZen

NASDAQ: GILD
Gilead Sciences Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Gilead Sciences earnings were $480.0M for the trailing 12 months ending Dec 31, 2024, with -91.6% growth year over year. The latest GILD earnings report on Dec 31, 2024 announced Q4 2024 earnings of $1.8B, up 42.3% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, GILD reported annual earnings of $480.0M, with -91.5% growth. The next GILD earnings date is May 8, 2025.

GILD past earnings growth

How has GILD's earnings growth performed historically?

Company
-91.63%
Industry
373.66%
Market
64.82%
GILD's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
GILD's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
GILD's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

GILD earnings history

Current Revenue
$28.8B
Current Earnings
$480.0M
Current Profit Margin
1.7%
GILD's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

GILD Return on Equity

Current Company
2.6%
Current Industry
40.7%
Current Market
34.2%
GILD's Return on Equity (2.6%)... subscribe to Premium to read more.
High Return on Equity Performance

GILD undefined

Current Company
0.9%
Current Industry
8.3%
GILD is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when GILD announces earnings.

GILD undefined

Current Company
3.55%
Current Industry
14.7%
GILD's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

GILD vs General Drug Manufacturer Stocks

TickerEBITDAEarningsY/Y EarningsEPS
GILD$4.44B$480.00M-38.27%$0.38
SNY$11.90B$5.79B+13.35%$2.31
PFE$15.02B$8.03B-13.19%$1.42
BMY$1.21B-$8.95BN/A-$4.41
AMGN$13.36B$4.09B-10.08%$7.62
View Top General Drug Manufacturer Stocks

GILD earnings dates

Next earnings date
May 8, 2025

Gilead Sciences Earnings Reports & History FAQ

What were Gilead Sciences's earnings last quarter?

On GILD's earnings call on Invalid Date, Gilead Sciences (NASDAQ: GILD) reported Q4 2024 earnings per share (EPS) of $1.42, up 23.48% year over year. Total GILD earnings for the quarter were $1.78 billion. In the same quarter last year, Gilead Sciences's earnings per share (EPS) was $1.15.

If you're new to stock investing, here's how to buy Gilead Sciences stock.

When does Gilead Sciences report earnings?

The next GILD earnings call is Invalid Date. Add GILD to your watchlist to be reminded of Gilead Sciences's next earnings date.

What was GILD's earnings growth in the past year?

As of Gilead Sciences's earnings date in Invalid Date, Gilead Sciences's earnings has grown -91.63% year over year. This is 465.29 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 373.66%. GILD earnings in the past year totalled $480.00 million.

Is Gilead Sciences profitable or losing money?

As of the last Gilead Sciences earnings report, Gilead Sciences is currently profitable. Gilead Sciences's net profit (also called net income) for the twelve months ending Dec 31, 2024 was $480.00 million, a 91.53% decrease year over year.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.